Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nucleoside-Modified mRNA Vaccines Protect IFNAR –/– Mice against Crimean-Congo Hemorrhagic Fever Virus Infection
Sofia Appelberg, Lijo John, Norbert Pardi, et al.
Journal of Virology (2021) Vol. 96, Iss. 3
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Crimean–Congo haemorrhagic fever virus
David W. Hawman, Heinz Feldmann
Nature Reviews Microbiology (2023) Vol. 21, Iss. 7, pp. 463-477
Open Access | Times Cited: 115
The use of RNA-based treatments in the field of cancer immunotherapy
Mohammad Chehelgerdi, Matin Chehelgerdi
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 76
Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity
Liusheng Wu, Xiaoqiang Li, Xinye Qian, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 186-186
Open Access | Times Cited: 53
Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge
Shanna Leventhal, Kimberly Meade‐White, Deepashri Rao, et al.
EBioMedicine (2022) Vol. 82, pp. 104188-104188
Open Access | Times Cited: 45
mRNA vaccines for infectious diseases — advances, challenges and opportunities
Norbert Pardi, Florian Krammer
Nature Reviews Drug Discovery (2024)
Closed Access | Times Cited: 11
Single dose, dual antigen RNA vaccines protect against lethal Crimean-Congo haemorrhagic fever virus infection in mice
Shanna Leventhal, Kimberly Meade‐White, Carl Shaia, et al.
EBioMedicine (2024) Vol. 101, pp. 105017-105017
Open Access | Times Cited: 8
Nucleocapsid protein-specific monoclonal antibodies protect mice against Crimean-Congo hemorrhagic fever virus
Aura R. Garrison, Vanessa Moresco, Xiankun Zeng, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Crimean-Congo Hemorrhagic Fever Virus for Clinicians—Diagnosis, Clinical Management, and Therapeutics
Maria G. Frank, Gretchen Weaver, Vanessa Raabe
Emerging infectious diseases (2024) Vol. 30, Iss. 5
Open Access | Times Cited: 8
A replicating RNA vaccine confers protection in a rhesus macaque model of Crimean-Congo hemorrhagic fever
David W. Hawman, Shanna Leventhal, Kimberly Meade‐White, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Induced protection from a CCHFV-M DNA vaccine requires CD8+ T cells
Joseph W. Golden, Collin J. Fitzpatrick, John J. Suschak, et al.
Virus Research (2023) Vol. 334, pp. 199173-199173
Open Access | Times Cited: 20
Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model
Jack E. Saunders, Ciarán Gilbride, Stuart Dowall, et al.
EBioMedicine (2023) Vol. 90, pp. 104523-104523
Open Access | Times Cited: 19
CCHFV vaccine development, current challenges, limitations, and future directions
Büşra Ahata, Günseli Bayram Akçapınar
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control
Shen Wang, Wujian Li, Zhenshan Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
Recent Advances in Crimean-Congo Hemorrhagic Fever Virus Detection, Treatment, and Vaccination: Overview of Current Status and Challenges
Khursheed Muzammil, Saba Rayyani, Ahmed Abbas Sahib, et al.
Biological Procedures Online (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 5
Interventions for the control of Crimean-Congo hemorrhagic fever and tick vectors
José de la Fuente, S. Ghosh, Laetitia Lempereur, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 5
Accelerated DNA vaccine regimen provides protection against Crimean-Congo hemorrhagic fever virus challenge in a macaque model
David W. Hawman, Kimberly Meade‐White, Shanna Leventhal, et al.
Molecular Therapy (2022) Vol. 31, Iss. 2, pp. 387-397
Open Access | Times Cited: 23
A replicating RNA vaccine confers protection in a rhesus macaque model of Crimean-Congo hemorrhagic fever
David W. Hawman, Shanna Leventhal, Kimberly Meade‐White, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 4
The Adaptive Immune Response against Bunyavirales
Reem Alatrash, Bobby Brooke Herrera
Viruses (2024) Vol. 16, Iss. 3, pp. 483-483
Open Access | Times Cited: 4
Potential of mRNA-based vaccines for the control of tick-borne pathogens in one health perspective
Elizabeth González-Cueto, José de la Fuente, César López‐Camacho
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus
Gabrielle Scher, Dennis A. Bente, Megan C. Mears, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 12
Vaccination with the Crimean-Congo hemorrhagic fever virus viral replicon vaccine induces NP-based T-cell activation and antibodies possessing Fc-mediated effector functions
Florine E. M. Scholte, Ercan Karaaslan, Justin T. O’Neal, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 12
Crimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development
Aykut Özdarendeli
Diagnostics (2023) Vol. 13, Iss. 16, pp. 2708-2708
Open Access | Times Cited: 11
Research and product development for Crimean–Congo haemorrhagic fever: priorities for 2024–30
Amanda Semper, James Olver, J. O. Warner, et al.
The Lancet Infectious Diseases (2024)
Closed Access | Times Cited: 3
Advances and perspectives in the development of vaccines against highly pathogenic bunyaviruses
Tong Chen, Zhe Ding, Jiaming Lan, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 7
Crimean Congo hemorrhagic fever virus nucleoprotein and GP38 subunit vaccine combination prevents morbidity in mice
Elif Karaaslan, Teresa E. Sorvillo, Florine E. M. Scholte, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top